Glaucoma implant trial halted early – what we know
NCT ID NCT04770324
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new medical device called Supraflow v1.3, which is implanted in the eye to help drain fluid and lower pressure in people with open-angle glaucoma. The trial included 22 patients whose eye pressure was not controlled with medication. However, the study was terminated early, so the full safety and effectiveness of the implant remain unclear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Supraflow v1.3 medical device (interposition supraciliary implant)
- What this could lead to
- If successful, this implant could offer a new surgical option to lower eye pressure in glaucoma patients who don't respond well to eye drops.
- What could go wrong
- The trial was terminated early with only 22 participants, so we don't have enough data to know if it works or is safe. Surgery always carries risks like infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA, OPEN-ANGLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Malayan Center
Yerevan, 0033, Armenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bangkok community eye check reveal hidden glaucoma risks?
- Can a laser treat glaucoma without touching the eye?
- Micro-Coil stent aims to drain glaucoma pressure during cataract surgery
- Eye implant could replace daily drops for glaucoma
- Eye strain test may forecast glaucoma course
- Eye drop combo study for glaucoma halted early